Glycoprotein News and Research

RSS

COVID-19 infection risk and outcomes explained by the cell receptor genetic variability

Genetic variants in the angiotensin‐converting enzyme 2 (ACE2) receptor, utilized by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) for cell entry, are predicted to either encourage or inhibit interaction with viral proteins and subsequently contribute to genetic risk in coronavirus disease (COVID-19). This is the key finding of a new study available on the preprint server bioRxiv*.

5 May 2020

Spike protein analysis from India's first SARS-CoV-2

A new study published on the preprint server bioRxiv analyzes viral spike protein sequences from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak in West Bengal, India, comparing them with sequences from other Indian states and Wuhan, China.

30 Apr 2020

Synthetic antibodies constructed using bacterial superglue could help fight lethal viruses

Synthetic antibodies constructed using bacterial superglue can neutralize potentially lethal viruses, according to a study published on April 21 in eLife.

28 Apr 2020

Research looks at best ways to tackle coronavirus crisis

A new study published in the journal Frontiers in Microbiology in April 2020 discusses the most attractive approaches among the broad spectrum of experimental and theoretical strategies being worked on to counter the COVID-19 pandemic.

24 Apr 2020

Scientists identify new mechanisms that offer protection against Marburg infection

A detailed study of the monoclonal antibodies from a person who survived a Marburg infection led researchers to identify novel mechanisms that contribute protection against the disease, according to the latest findings of a collaborative team led by The University of Texas Medical Branch at Galveston and Vanderbilt University Medical Center.

22 Apr 2020

Difference between flu and novel coronavirus disease

Both influenza and COVID-19 disease are caused by infectious respiratory agents and cause symptoms that can look quite similar. Coronaviruses cause both. So, what’s the difference?

21 Apr 2020

Mutations in novel coronavirus make it more dangerous

A new report published on the preprint server medRxiv in April 2020 reveals that the novel coronavirus SARS-CoV-2 shows the presence of new mutations acquired within infected human cases, which significantly increase its ability to cause human disease.

20 Apr 2020

A novel method for predicting promising antiviral drug or vaccine targets

A novel method to predict the most promising targets for antiviral drugs or vaccines is based on the conformational changes viral glycoproteins go through during the process of recognition and binding to the host cell.

20 Apr 2020

Research suggests Nelfinavir and Cepharanthine as potential anti-SARS-CoV-2 agents

A new study published in the journal bioRxiv in April 2020 reports the identification of a promising multidrug treatment against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for causing COVID-19 disease. The team predicts that this combination will prevent the virus from reproducing, hence both halting the transmission and progress of the disease.

19 Apr 2020

Computer simulations yield promising vaccine candidate against SARS-CoV-2

In a recent study that appeared on a preprint server bioRxiv, scientists from India designed a multi-epitope peptide-based vaccine that predicted high immunogenic response in the population.

19 Apr 2020

Potential universal Ebola vaccine may neutralize all four harmful virus species

Infectious disease scientists report early development of a potential universal vaccine for Ebola viruses that preclinical tests show might neutralize all four species of these deadly viruses infecting people in recent outbreaks, mainly in Africa.

16 Apr 2020

Anosmia (loss of smell) confirmed as a clinical feature of COVID-19

Earlier last month, the association of ear, nose, and throat (ENT) specialists in the UK issued a public statement advising patients with a sudden loss of smell or taste to get tested for COVID-19. They cited not only their own observations but those from numerous other ENT consultants the world around. A review of multiple papers on the sinus and nasal symptoms and signs related to the diagnosis of COVID-19, published in April 2020, in the journal Laryngoscope Investigative Otolaryngology, reiterates this finding.

15 Apr 2020

'Chaperone protein' protects against autoimmune diseases, mice study shows

Like a parent of teenagers at a party, Mother Nature depends on chaperones to keep one of her charges, the immune system, in line so that it doesn't mistakenly attack normal cells, tissues and organs in our bodies.

15 Apr 2020

PIV5-based MERS vaccine shows promise for COVID-19

The coronavirus disease (COVID-19) has spread to 184 countries and territories. Currently, there is no vaccine available for COVID-19 disease, or SARS-CoV-2 infection. However, scientists around the world are racing to find ways to block the virus.

8 Apr 2020

Scientists find important clues to vaccine in SARS-CoV-2 genome

A new research paper published by scientists at the University of Bristol who sequenced the genome of the SARS-CoV-2 virus, which is causing the worldwide COVID-19 illness, reveals some significant findings that could help researchers working on rolling out vaccines to stop the relentless march of the virus. The study was published online on the preprint site bioRxiv in April 2020.

2 Apr 2020

What are coronaviruses and COVID-19?

The current COVID-19 pandemic is caused by a novel coronavirus called SARS-CoV-2, or severe acute respiratory syndrome coronavirus 2. Coronavirus disease 2019 (COVID-19) is an infectious disease caused by SARS-CoV-2.

1 Apr 2020

Celltrion announces key milestones in its efforts to fight COVID-19

Celltrion Group today announced key milestones in its efforts to fight the 2019 novel coronavirus (COVID-19) pandemic.

23 Mar 2020

CEL-SCI collaborates with UGA Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy

CEL-SCI Corporation announced today it has signed a collaboration agreement with the University of Georgia’s Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy.

23 Mar 2020

Pediatric Infectious Disease Journal review: COVID-19 appears less severe in children

As outbreaks of COVID-19 disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue worldwide, there's reassuring evidence that children have fewer symptoms and less severe disease.

13 Mar 2020

NCAM2 protein is a vital factor in the formation of cerebral cortex, neuronal morphogenesis

The molecule NCAM2, a glycoprotein from the superfamily of immunoglobulins, is a vital factor in the formation of the cerebral cortex, neuronal morphogenesis and formation of neuronal circuits in the brain, as stated in the new study published in the journal Cerebral Cortex.

13 Mar 2020